Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Microglia and Oxidative Neuroprotection: Full Study

Previous related pageVitamin D, Microglia and Oxidative Neuroprotection: Study SummaryNext related pageVitamin D, Microglia and Oxidative Neuroprotection: Study Summary
Study at a glance

How was vitamin D tested in nerve cells, brain immune cells and worms?

Researchers used rodent nerve cells grown in the laboratory, microglia and small worms to study vitamin D-related responses to injury. Microglia are immune cells found in the brain. The cell experiments tested active vitamin D and changes in the amount of vitamin D receptor, the protein that receives its signal. The worm experiments used vitamin D3 and different genetic changes.

Did active vitamin D reduce signs of cell injury?

Active vitamin D and extra receptor reduced selected signs of chemical stress in nerve cells exposed to a toxin. They also reduced some signals of inflammation and damage to cell membranes in challenged microglia. These laboratory measurements did not directly show preserved brain tissue, improved long-term nerve-cell survival or recovery in a person. The microglial challenge contained material released by other cells grown in the laboratory, not just one purified protein.

Could the enzyme DUB3 help the vitamin D receptor last longer?

DUB3 is an enzyme that changes how other proteins are handled. Increasing it made the vitamin D receptor last longer and reduced some injury-related signals. This supports a possible link between how long the receptor lasts and how cells respond. It did not prove every molecular step or show that all of DUB3’s effects required the vitamin D receptor. Other targets could contribute.

Do these findings show a treatment for Parkinson’s disease?

The worm experiments showed changes in selected injury and behaviour measurements, but worms do not reproduce a human brain or its microglia. Some reported methods were inconsistent, and the experiments were repeated independently only a few times. The findings suggest mechanisms for further testing. They do not establish prevention or treatment of Parkinson’s disease, a supplement dose, a blood vitamin D target or that activating the receptor more strongly is always beneficial.

Read the full article below ↓

Can vitamin D receptor signalling influence both neuronal oxidative injury and the inflammatory response of microglia? Zheng and colleagues tested this question in cultured cells and several worm models. Their experiments identify receptor-related responses and a protein-stability mechanism worth investigating, but they do not establish neuroprotection in patients. For the shorter account, read Vitamin D, Microglia and Oxidative Neuroprotection: Study Summary.

Two interacting questions, tested in different systems

Neurons and microglia have different functions within the brain. Neurons transmit information, while microglia are resident immune cells that respond to disturbances in their environment. A substance can change a neuronal injury signal without changing microglial behaviour, or the reverse. Demonstrating both effects in separate experiments is useful, but does not automatically demonstrate a complete protective circuit in an intact brain.

The 2024 study examined vitamin D receptors, abbreviated VDR, and DUB3, an enzyme that removes ubiquitin modifications from proteins. Ubiquitin is a small protein that can help regulate the fate of other proteins, including their degradation. The investigators proposed that DUB3 stabilises VDR and thereby supports neuronal resistance to injury and restraint of microglial inflammation. The experiments provide evidence for parts of that proposal, with important gaps between those parts.

What was exposed to what

The neuronal experiments used primary rodent cortical cultures and MN9D, a mouse dopaminergic cell line. Rotenone, a mitochondrial toxin, was used at 2 micromolar for 24 hours in the principal cell-injury protocol. Calcitriol, the active vitamin D hormone, was applied at 100 nanomolar for 24 hours. Other conditions artificially increased VDR expression or reduced it using small interfering RNA, a method that lowers production of a selected protein.

This is not a model of ordinary oral supplementation. Direct active-hormone exposure bypasses the absorption, metabolism, transport and tissue regulation that occur in a person. Increasing a receptor experimentally is also different from increasing blood vitamin D. The receptor overview helps separate the presence of a signalling system from the question of how strongly that system responds under a particular exposure.

Microglial experiments used primary cultures and the BV2 mouse cell line. These cells received conditioned medium from MN9D cells engineered to produce more alpha-synuclein, a protein relevant to Parkinson’s disease biology. Conditioned medium is the fluid surrounding cultured cells, containing material those cells release. The investigators detected alpha-synuclein aggregates in it, but the exposure was not a purified preparation containing only that protein.

Neuronal oxidant signals and mitochondrial measurements

Rotenone increased fluorescence from an oxidant-sensitive probe. VDR overexpression and calcitriol treatment reduced that signal, while VDR knockdown increased it. Experiments included untreated controls and a control RNA sequence alongside the targeted knockdown. The principal neuronal figure reports at least five biologically independent replicates, with individual observations and means accompanied by standard errors. The supporting MN9D experiments showed a similar direction of response.

The probe, DCFH-DA, is useful for detecting changes in cellular oxidation-related fluorescence, but its signal is not a direct inventory of every reactive oxygen species. A reduction cannot by itself identify the chemical source, prove that all oxidative damage has been repaired or quantify preserved brain tissue. Connecting this measurement with oxidative stress requires retaining the distinction between an assay signal and the broader biological process.

The investigators also used JC-1, a dye whose fluorescence pattern reflects mitochondrial membrane potential. Rotenone shifted the pattern toward loss of that potential; VDR overexpression and calcitriol partly opposed the shift. These results complement the oxidant measurements. However, membrane potential is not the same outcome as respiratory capacity, energy production, long-term neuron survival or preserved behaviour. None should be substituted for another without a direct measurement.

Microglial inflammatory responses were also altered

The conditioned-medium challenge increased signals related to NLRP3 and ASC, proteins involved in assembling an inflammasome. An inflammasome is a molecular complex that can activate inflammatory enzymes and downstream responses. VDR overexpression or calcitriol reduced the measured fluorescence for these proteins and reduced caspase-1 activity. VDR knockdown generally shifted the responses in the opposite direction. The principal microglial experiments reported at least three biologically independent replicates.

Additional measurements examined membrane injury. More challenged cells admitted propidium iodide, a dye normally excluded by intact membranes, and more lactate dehydrogenase was released into the medium. The protective conditions reduced these responses. In Figure 2H, the plotted mean enzyme-release rate is approximately 54% under the challenge and 35% with calcitriol, compared with roughly 30% with VDR overexpression and 19% with both interventions. These are approximate readings of the graph, not exact raw-data estimates or percentages of protected brain tissue. The BV2 supplementary experiments also measured transcripts for inflammatory components and cytokines. These observations support a response involving inflammatory signalling, rather than a claim that every aspect of microglial activation was normalised.

Several boundaries matter. More NLRP3 staining is not identical to direct observation of complete inflammasome assembly. Membrane permeability and enzyme leakage are not exclusive markers of a single cell-death pathway. Measuring cytokine messenger RNA does not establish the amount of mature cytokine released. The combined pattern is biologically informative, but each assay contributes a limited piece of evidence and retains its own specificity limits.

DUB3 provides a protein-stability hypothesis

The study then examined why receptor abundance might change. Increasing DUB3 raised VDR protein abundance, whereas reducing DUB3 lowered it. VDR messenger RNA did not change significantly in the corresponding experiment. That distinction points toward regulation after the message has been made, rather than simply increased transcription of the receptor gene. It is an example of why gene expression and protein abundance should not be treated as interchangeable measurements.

A protein-turnover experiment used cycloheximide to inhibit new protein synthesis. VDR persisted longer when DUB3 was increased and declined more rapidly when DUB3 was reduced. Immunoprecipitation experiments, which isolate proteins and associated material from cell extracts, linked DUB3 with VDR and showed changes in receptor-associated ubiquitin signals. The researchers also tested shortened protein constructs to identify regions involved in the association.

These results support a relationship between DUB3, receptor stability and ubiquitination. They do not establish every molecular step with purified proteins. Association within a cell extract can involve additional partners, and a shortened construct can change folding as well as remove an interaction site. The data are therefore stronger than a simple correlation between two protein levels, while remaining short of a complete biochemical reconstruction.

DUB3 overexpression also reduced neuronal oxidant signals and several microglial injury responses, whereas knockdown worsened them. These experiments were performed alongside the receptor experiments, and the paper states that some measurements were parallel. They should not be counted as an entirely independent replication programme. Crucially, the reported design does not demonstrate that removing VDR abolishes every protective DUB3 effect. Other DUB3 targets could contribute.

What the worm experiments add

The investigators also used Caenorhabditis elegans, a small nematode worm, with several genetically defined strains. Rotenone exposure was combined with measurements of labelled dopamine neurons, movement, attraction to an odour, survival and oxidation-related readouts. Different strains answered different questions. For example, the alpha-synuclein reporter in strain NL5901 was expressed in muscle, according to the supplementary strain table. Its fluorescence must not be described as aggregation measured in human brain neurons.

The worm experiments manipulated daf-12, described by the authors as a VDR ortholog, meaning an evolutionarily related gene. Reduced daf-12 expression worsened several toxin-associated outcomes, while vitamin D3 exposure improved selected measurements in other comparisons. Biological relatedness does not establish identical ligand binding or identical signalling in worms and humans. These experiments also do not test microglia, because the worm model is not a miniature mammalian brain with those immune cells.

The methods specify 6 micromolar rotenone and 400 micromolar vitamin D3 on growth plates, with a vehicle control. These exposures differ in both chemical form and context from calcitriol applied to mammalian cells. Behavioural counts included thirty worms per group, while chemotaxis used three groups of roughly one hundred worms. Those sample sizes describe different experimental units and cannot be combined into a single human-equivalent sample size.

Reporting details that affect confidence

Several descriptions prevent exact reconstruction without clarification from the authors. The primary-neuron methods name C57 mice but then refer to fetal rat cortex. The results describe adult-specific worm RNA interference, whereas the methods describe exposure beginning at the first larval stage. The ubiquitination methods and a figure legend also differ over the concentration of the proteasome inhibitor MG132. This appraisal does not silently resolve those disagreements.

The statistical methods report one-way analysis of variance followed by a post hoc comparison procedure, without naming that procedure. The paper examines many endpoints across multiple systems, but does not describe a comprehensive adjustment across that entire programme. Standard-error bars show uncertainty around estimated means; they do not display the full spread of individual responses. Small replicate numbers and incomplete reporting make precise generalisation less secure than the number of figures might suggest.

The supplementary material was available and examined, including the additional cell experiments, knockdown checks, strain and reagent tables, and uncropped blots. This improves access to the reported work, but inspecting published images is not the same as independently reproducing experiments or validating all raw measurements. The article reports public research funding from Chinese national and Jiangsu provincial programmes, and the authors declare no competing interests.

What the evidence supports

The strongest conclusion concerns model-specific biology: receptor manipulation and active-hormone exposure altered selected neuronal and microglial responses, while DUB3 influenced receptor stability. The findings fit a broader question about neuroendocrine integration, but the study did not measure whole-body hormonal feedback, human brain exposure or a clinical neurological outcome. Those connections remain research questions.

The evidence hierarchy keeps the conclusion proportional. This is a mechanistic study using cells and worms, not a trial of Parkinson’s disease prevention or treatment. It provides candidates for further testing, including experiments that establish pathway necessity and reproduce the effects in more representative systems. It establishes neither a supplement dose nor a blood concentration target, and it does not show that more receptor stimulation is always beneficial.

Scientific sources

Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X, Ruan Q, Li L, Guo J. VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease. Cell Death Discovery. 2024;10:150. DOI: 10.1038/s41420-024-01912-9. PMID: 38514643. The complete principal paper, seven figures, supplementary figures S1: S8 and supplementary tables S1: S3 were examined.

Related reading

Original sources

Source

VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease

Published in Cell Death Discovery (2024).

Publication details

Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X, Ruan Q, Li L, Guo J. VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease. Cell Death Discovery. 2024;10:150. DOI: 10.1038/s41420-024-01912-9. PMID: 38514643. The complete principal paper, seven figures, supplementary figures S1: S8 and supplementary tables S1: S3 were examined.

Read more →